Overview
Sir Henry H. Dale first identified oxytocin and its uterine contractile properties in 1906. Like all other neurohypophysial hormones, oxytocin is composed of nine amino acids with a disulfide bridge between the Cys 1 and 6 residues. In the mid-1950s, synthetic oxytocin was successfully synthesized by a biochemist named Vincent du Vigneaud; he was later recognized with a Nobel prize for his work. Oxytocin continues to be an important tool in modern obstetrics to induce labor when indicated and to manage postpartum hemorrhage. It is estimated that labor induction with oxytocin is used in almost 10% of deliveries globally. It should be noted that there are risks associated with oxytocin intervention during childbirth. Oxytocin should be used judiciously only when necessary and by experienced healthcare practitioners. Although most commonly linked to labor and delivery, oxytocin actually has broad peripheral and central effects. It plays an important role in pair bonding, social cognition and functioning, and even fear conditioning. Oxytocin also serves a role in metabolic homeostasis and cardiovascular regulation.
Indication
Administration of exogenous oxytocin is indicated in the antepartum period to initiate or improve uterine contractions for vaginal delivery in situations where there is fetal or maternal concern. For example, It may be used to induce labor in cases of Rh sensitization, maternal diabetes, preeclampsia at or near term, and when delivery is indicated due to prematurely ruptured membranes. Importantly, oxytocin is not approved or indicated for elective induction of labor. Oxytocin may be used to reinforce labor in select cases of uterine inertia and as adjunctive therapy in the management of incomplete or inevitable abortion. In the postpartum period, oxytocin may be used to induced contractions in the 3rd stage of labor and to control postpartum bleeding or hemorrhage.
Associated Conditions
- Incomplete Abortion
- Inevitable abortion
- Postpartum Bleeding
Research Report
Oxytocin (DB00107): A Comprehensive Monograph on its Pharmacological, Clinical, and Neuroscientific Profile
Executive Summary
Oxytocin is a cyclic nonapeptide hormone and neuromodulator with a dual identity that defines its clinical and investigational landscape. As a peripherally acting hormone, it is an indispensable and potent uterotonic agent, classified as a biotech drug and protein-based therapy. Its primary, FDA-approved clinical applications are in obstetrics, where it is used to induce or augment labor, manage inevitable or incomplete abortions, and, most critically, to control and prevent postpartum hemorrhage (PPH). The administration of oxytocin in this context is characterized by a narrow therapeutic index and significant risks, including uterine hyperstimulation, fetal distress, and maternal water intoxication. Consequently, its use demands strict adherence to clinical protocols, including administration via calibrated infusion pump and continuous maternal and fetal monitoring.
Centrally, oxytocin functions as a neurotransmitter within the brain, modulating a complex array of social and emotional behaviors. Often dubbed the "love hormone," its role is more accurately described as a facilitator of social salience, with effects that are highly dependent on individual and contextual factors. This central activity has spurred a vast field of research investigating its therapeutic potential for neuropsychiatric disorders characterized by social deficits, such as autism spectrum disorder (ASD), anxiety disorders, and depression. Despite decades of study, the evidence for these applications remains largely inconclusive and often contradictory. Clinical trials have been hampered by inconsistent findings, methodological challenges related to drug delivery to the brain, and a lack of standardized assays for measuring endogenous oxytocin.
Clinical Trials
View More Clinical Trials
Sign in to access the complete clinical trial database with detailed study information.
Title | Posted | Study ID | Phase | Status | Sponsor |
---|---|---|---|---|---|
2015/02/11 | Early Phase 1 | Withdrawn | |||
2015/01/30 | Phase 2 | UNKNOWN | |||
2015/01/14 | Not Applicable | Completed | Samuel Lunenfeld Research Institute, Mount Sinai Hospital | ||
2014/12/18 | Phase 3 | UNKNOWN | |||
2014/12/17 | Phase 2 | Completed | |||
2014/12/11 | Not Applicable | Completed | |||
2014/12/03 | Phase 3 | UNKNOWN | |||
2014/12/01 | Phase 3 | Completed | |||
2014/12/01 | Phase 3 | Completed | |||
2014/11/27 | Phase 3 | UNKNOWN |
FDA Drug Approvals
View More FDA Approvals
Sign in to access additional FDA-approved drug information with detailed regulatory data.
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
---|---|---|---|---|---|
No FDA approvals found for this drug. |
EMA Drug Approvals
View More EMA Approvals
Sign in to access additional EMA-approved drug information with detailed regulatory data.
Approved Product | Authorization Holder | Status | Issued Date |
---|---|---|---|
No EMA approvals found for this drug. |
HSA Drug Approvals
View More HSA Approvals
Sign in to access additional HSA-approved drug information with detailed regulatory data.
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No HSA approvals found for this drug. |
NMPA Drug Approvals
View More NMPA Approvals
Sign in to access additional NMPA-approved drug information with detailed regulatory data.
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
---|---|---|---|---|---|
No NMPA approvals found for this drug. |
PPB Drug Approvals
View More PPB Approvals
Sign in to access additional PPB-approved drug information with detailed regulatory data.
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
---|---|---|---|---|---|
No PPB approvals found for this drug. |
TGA Drug Approvals
View More TGA Approvals
Sign in to access additional TGA-approved drug information with detailed regulatory data.
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
---|---|---|---|---|---|
No TGA approvals found for this drug. |
Help Us Improve
Your feedback helps us provide better drug information and insights.